Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
6 Months : From Jul 2019 to Jan 2020
By Colin Kellaher
Arrowhead Pharmaceuticals Inc. (ARWR) on Wednesday said it earned a $25 million milestone payment after a unit of Johnson & Johnson (JNJ) began a phase 2b combination study in patients with chronic hepatitis B infection.
The Pasadena, Calif., drug developer said J&J's Janssen Pharmaceuticals unit has begun dosing in the study of different combination regimens, including JNJ-3989, formerly ARO-HBV.
Arrowhead in October agreed to work with Janssen to develop and commercialize ARO-HBV as part of a license and collaboration agreement potentially worth more than $3.7 billion to Arrowhead.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
August 28, 2019 09:07 ET (13:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.